Irbesartan
From Free net encyclopedia
Current revision
|
[[Image:{{{image|Irbesartan.png}}}|{{{width|220}}}px|Irbesartan chemical structure]] | |
| 2-butyl- 3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]- 1,3-diazaspiro[4.4]non-1-en-4-one IUPAC name | |
| CAS number 138402-11-6 | }}} |
| PubChem 3749 | DrugBank APRD00413 |
| Chemical formula | C25H28N6O |
| Molecular weight | 428.53 |
| Bioavailability | 60–80% |
| Metabolism | hepatic (CYP2C9) |
| Elimination half-life | 11–15 hours |
| Excretion | renal 20%, faecal 65% |
| Pregnancy category | D (Aust) |
| Legal status | Schedule 4 (Aust) |
| Routes of administration | oral |
Irbesartan (rINN) (IPA: Template:IPA) is an angiotensin II receptor antagonist used mainly for the treatment of hypertension. Irbesartan was developed by Sanofi Research (now part of Sanofi Aventis). It is jointly marketed by Sanofi Aventis and Bristol-Myers Squibb under the trade names Aprovel, Karvea, and Avapro.
Contents |
Clinical use
- Main article: Angiotensin II receptor antagonist
Indications
As with all angiotensin II receptor antagonists, irbesartan is indicated for the treatment of hypertension. Irbesartan may also delay progression of diabetic nephropathy and is also indicated for the reduction of renal disease progression in patients with type 2 diabetes, hypertension and microalbuminuria (>30 mg/24 hours) or proteinuria (>900 mg/24 hours). (Rossi, 2006)
Combination with diuretic
Irbesartan is also available in a combination formulation with a low dose thiazide diuretic, invariably hydrochlorothiazide, to achieve an additive antihypertensive effect. Irbesartan/hydrochlorothiazide combination preparations are marketed under similar trade names to irbesartan preparations, including CoAprovel, Karvezide and Avapro HCT.
References
- Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3